title: RIPK3-a predictive marker for personalized immunotherapy?
abstract: Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells. This proposes RIPK3 as a novel predictive marker for personalization of cancer immunotherapy.
authors.affiliation: Institute of Virology, Saarland University , Homburg/Saar, Germany.
authors.forename: Sigrun
authors.initials: S
authors.lastname: Smola
keywords: Cancer; Dendritic cells; Immune response; RIPK3; dsRNA